Search - tctmd.com

Displaying 41 - 51 of 51

Sort: Relevancy | Date

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

News Daily News

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Yael L. Maxwell

January 31, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

December 30, 2016

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

News Daily News

PCSK9的变体与低LDL胆固醇和糖尿病风险增加相关

Michael O'Riordan

December 01, 2016

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

News Daily News

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

Michael O'Riordan

December 01, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.